Biotech
First Time Investor Applies Bio Run-Up Strategy: $DCTH $CLDX $ACCP.OB $CADX $EXAS $RPRX
Written by Tyler Trimbath. First time traders and investors need to rely on a solid strategy to gain market knowledge. Several months ago I became interested in trading and needed to find a niche strategy that was easy to understand and would allow me to have large returns I was looking for. The bio run-up [...]
Continue reading...History of Success Trading FDA Catalyst Events: $CAMH, $AEN, $NVLT, $GTHP, $CTIC
1 June 2010 – 3:49 pm PST
Comments Off
Written by Mark Messier (BioRunUp.com). I would like to point out some of the benefits that I personally have experienced by taking advantage of my membership to Mike Havrilla’s website at MikeHavRX.com over the past year. Lets take a look at some of my picks using Mike’s Biotech Regulatory Catalyst Index and how they have performed. If [...]
Continue reading...Trading FDA, Clinical Trial Binary Events: $ABT $CXM $AIS $ARNA $OREX $VVUS $BDSI
31 May 2010 – 6:18 am PST
A common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than $1 billion market cap stocks) with pending binary events (e.g. FDA decision or clinical trial results) approximately 3-6 months ahead of the expected catalyst date and sell into the expected upward momentum in both [...]
Continue reading...A Variety of Strategies for Trading FDA, Clinical Trial News
27 May 2010 – 12:24 pm PST
Comments Off
Beyond the strategy of selecting a basket of small/micro-cap stocks with pending binary events such as FDA decisions and clinical trial results, another means of achieving diversification is by selecting a basket of companies with different types of pending catalysts. Below are some examples of how to categorize pending bio-catalyst events and some specific examples [...]
Continue reading...Near-Term Extreme FDA, Clinical Trial Trades: $GNBT $NBIX $NRGX.OB $GTXI
23 May 2010 – 11:14 am PST
Comments Off
Below is a selection of companies with stock prices below $5 per share and upcoming binary events in the form of FDA news / decisions or clinical trial results that are expected within the next three months. A common strategy used by many investors is to buy a basket of several small or micro-cap companies [...]
Continue reading...FDA Panel to Review Menthol Cigarettes, Dissolvable Tobacco Products
22 May 2010 – 12:32 pm PST
Comments Off
In mid-July, the FDA Tobacco Products Scientific Advisory Committee will meet to discuss dissolvable tobacco products and menthol cigarettes ahead of required reports to the Secretary of Health and Human Services regarding the public health impact of these products. Tobacco industry presentations on menthol in cigarettes will include the following: the characterization of menthol, the [...]
Continue reading...Abbott Expands Emerging Market Generic Drug Presence with Piramal Acquisition
21 May 2010 – 5:18 pm PST
Comments Off
Abbott Labs (NYSE:ABT) is poised to become the top pharmaceutical company in India, following its acquisition of Piramal’s healthcare solutions business. The deal follows a collaboration announced last week between Abbott and India-based Zydus Cadila. Abbott also announced the establishment of a stand-alone established products division which accounts for over $5 billion in sales. The [...]
Continue reading...FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin Pharma
19 May 2010 – 6:00 pm PST
Earlier today, Discovery Labs (NASDAQ:DSCO) announced that the re-validation has been completed for the Biological Activity Test (BAT) for quality control and stability for SURFAXIN (lucinactant). DSCO has submitted a protocol to the FDA, outlining its plans for preclinical studies and expects feedback from the Agency in June. The Company affirmed its prior guidance for [...]
Continue reading...FDA, Clinical Trial News: Forest Labs, Nycomed, NexMed
17 May 2010 – 5:45 pm PST
Comments Off
After the market close, Forest Labs (NYSE:FRX) and privately held Nycomed announced that a Complete Response Letter (CRL) was issued by the FDA for DAXAS (roflumilast) (a once-daily oral treatment) (PDE4 Enzyme Inhibitor). The NDA is seeking FDA approval as treatment to reduce chronic obstructive pulmonary disease (COPD) exacerbations associated with chronic bronchitis in patients [...]
Continue reading...Near-Term FDA, Clinical Trial Extreme Trades: $ACCP.OB, $APPY, $AVNR, $BMOD.OB, $CYCC
16 May 2010 – 7:00 am PST
Comments Off
Below is a selection of companies with stock prices below $5 per share and upcoming binary events in the form of FDA news / decisions or clinical trial results that are expected by mid-year. A common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than [...]
Continue reading...
1 June 2010 – 4:10 pm PST
View Comments